
Opinion|Videos|October 24, 2024
Clinical Presentation and Risk Factors
Author(s)Toby Maher, MD, PhD
Key Takeaways
- IPF diagnosis relies on clinical evaluation, HRCT, and occasionally lung biopsy to identify usual interstitial pneumonia patterns.
- The average time to IPF diagnosis can be delayed up to two years due to symptom overlap with other conditions.
Toby Maher, MD, PhD, discusses how common signs and symptoms of idiopathic pulmonary fibrosis (IPF) at diagnosis can indicate disease progression, while also identifying key risk factors associated with IPF and emphasizing the importance of modifying certain lifestyle factors to help prevent the disease.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What signs and symptoms of IPF are often present at diagnosis, and what patient characteristics at the time of diagnosis may be predictive of disease progression?
- What risk factors are associated with IPF, and what changes can be made to modifiable risk factors to prevent the disease?
Advertisement
Related to this article

Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.

Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.

Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.

The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.

Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.

AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.

Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
Secondary T-Cell Cancers After CAR T: Rare, Real, and Worth Watching
5



